Lundbeck has announced plans to to investigate Lu AA21004 for the treatment of depression in patients and will enrol the first patient in a 400 patient Phase II study by the end of third quarter 2006. The decision is based on positive pre-clinical results as well as positive conclusion of the Phase I trials in healthy individuals.

Lu AA21004 is the most advanced project in Lundbeck within a new chemical class, the bis-aryl-sulphanyl amines. The pharmacology of these projects is markedly different from any currently marketed antidepressants.

Compared with currently approved antidepressants preclinical models have demonstrated Lu AA21004 to address important unmet needs for patients on both fast onset of effect and increased efficacy.